![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
PERSPECTIVES IN PHARMACOLOGY
Department of Cell Biology and Neuroscience (M.K.K., B.L.F.), Graduate Program in Biomedical Engineering (M.K.K.), Rutgers University, Piscataway, New Jersey
Altered serum uric acid concentrations, both above and below normal levels, have been linked to a number of disease states. An abnormally high uric acid level has been correlated with gout, hypertension, cardiovascular disease, and renal disease, whereas a reduced uric acid concentration has been linked to multiple sclerosis, Parkinson's disease, Alzheimer's disease, and optic neuritis. Historically, uric acid has been considered a marker of these disease states. Recent studies, however, have provided evidence that uric acid may actually play a role in the development or progression of such diseases. As a result, the manipulation of uric acid concentrations is now either included in, or being investigated for, the treatment of a variety of disease states.
Address correspondence to: Dr. Bonnie L. Firestein, Department of Cell Biology and Neuroscience, Rutgers University, Piscataway, NJ 08854-8082. E-mail: firestein{at}biology.rutgers.edu
This article has been cited by other articles:
|
|
 |
|
  P. SOORIAKUMARAN, H. M. COLEY, S. B. FOX, P. MACANAS-PIRARD, D. P. LOVELL, A. HENDERSON, C. G. EDEN, P. D. MILLER, S. E.M. LANGLEY, and R. W. LAING A Randomized Controlled Trial Investigating the Effects of Celecoxib in Patients with Localized Prostate Cancer Anticancer Res, May 1, 2009; 29(5): 1483 - 1488. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. SOORIAKUMARAN, P. MACANAS-PIRARD, G. BUCCA, A. HENDERSON, S.E.M. LANGLEY, R.W. LAING, C.P. SMITH, E.E. LAING, and H.M. COLEY A Gene Expression Profiling Approach Assessing Celecoxib in a Randomized Controlled Trial in Prostate Cancer Cancer Genomics Proteomics, March 1, 2009; 6(2): 93 - 99. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. NEOGI, R. C. ELLISON, S. HUNT, R. TERKELTAUB, D. T. FELSON, and Y. ZHANG Serum Uric Acid Is Associated with Carotid Plaques: The National Heart, Lung, and Blood Institute Family Heart Study J Rheumatol, February 1, 2009; 36(2): 378 - 384. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Frank, T. W. George, J. K. Lodge, A. M. Rodriguez-Mateos, J. P. E. Spencer, A. M. Minihane, and G. Rimbach Daily Consumption of an Aqueous Green Tea Extract Supplement Does Not Impair Liver Function or Alter Cardiovascular Disease Risk Biomarkers in Healthy Men J. Nutr., January 1, 2009; 139(1): 58 - 62. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Anzai, K. Ichida, P. Jutabha, T. Kimura, E. Babu, C. J. Jin, S. Srivastava, K. Kitamura, I. Hisatome, H. Endou, et al. Plasma Urate Level Is Directly Regulated by a Voltage-driven Urate Efflux Transporter URATv1 (SLC2A9) in Humans J. Biol. Chem., October 3, 2008; 283(40): 26834 - 26838. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. H. Proctor Uric Acid and Neuroprotection Stroke, August 1, 2008; 39(8): e126 - e126. [Full Text] [PDF]
|
|
|
|
|
|
A. Bahn, Y. Hagos, S. Reuter, D. Balen, H. Brzica, W. Krick, B. C. Burckhardt, I. Sabolic, and G. Burckhardt Identification of a New Urate and High Affinity Nicotinate Transporter, hOAT10 (SLC22A13) J. Biol. Chem., June 13, 2008; 283(24): 16332 - 16341. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
